ReviewCancers2019
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.Journal of experimental & clinical cancer research : CR · 2026Article
- Effect of Bleomycin Hydrolase Expression in Tumor Tissue on the Therapeutic Effectiveness of Electrochemotherapy.Cancers · 2025Article
- Partial mitochondrial involvement in the antiproliferative and immunostimulatory effects of PT-112.Oncoimmunology · 2025Article
- IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HRNature cancer · 2025Article
- The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer.NPJ breast cancer · 2025Review
- Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response.Experimental hematology & oncology · 2024Article
- Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.Journal of medicinal chemistry · 2024Review
- Evaluating [International journal of molecular sciences · 2023Article
- Tumor Radiosensitization by Gene Electrotransfer-Mediated Double Targeting of Tumor Vasculature.International journal of molecular sciences · 2023Article
- Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.Nature communications · 2021Article
- Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells.STAR protocols · 2021Article
- Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ERClinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.Oncoimmunology · 2021Article
- Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.Nature communications · 2020Article
- Article
- EO771, the first luminal B mammary cancer cell line from C57BL/6 mice.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor-host interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting from the review of the literature could be a path towards the description of a precision experimental model of mammary cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.